Key facts
- This page summarizes David Malcom Rodman's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Jul 2024, 18:34.
David Malcom Rodman - 16 Jul 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- MLYS
- Reported as of
- 16 Jul 2024
- Net transaction value
- -$7,309
- SEC form
- 4
- Accepted by SEC
- 18 Jul 2024, 18:34:08 UTC
- Prior SEC filing
- 12 Jul 2024
- Next SEC filing
- 13 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam Levy, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Malcom Rodman filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 18 Jul 2024.
Change
- Previous filing in this sequence was filed on 12 Jul 2024.
- Current net transaction value: -$7,309.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MLYS
transaction
Common Stock
Options Exercise
- Transaction value
- $567
- Shares
- +525
- Change %
- +0.51%
- Price
- $1.08*
- Shares after
- 103,398
- Date
- 16 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
MLYS
transaction
Common Stock
Sale
- Transaction value
- $7,876
- Shares
- -525
- Change %
- -0.51%
- Price
- $15.00
- Shares after
- 102,873
- Date
- 16 Jul 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MLYS
transaction
Derivative
Stock Option
Options Exercise
- Transaction value
- $0
- Shares
- -525
- Change %
- -0.29%
- Price
- $0.000000
- Shares after
- 183,483
- Date
- 16 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 525
- Exercise price
- $1.08
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.
Footnote F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.01. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
Footnote F3
Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.
Footnote F4
The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.